A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Domestic private pharma companies are expecting robust industry legal changes to facilitate future initiatives.

Rising Pharmaceutical Innovation, AI Integration, and Point-of-Care Testing Applications Drive 9.8% CAGR Growth Across Healthcare and Biotechnology ...

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for ...

Regulatory science also plays a crucial role in ensuring public trust in these products and facilitating the translation of ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Understanding trade-offs can help countries better prepare for future health emergencies and treat chronic conditions ...

FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release opioids with abuse-deterrent formulations could lead to ...

China’s sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer (NYSE: PFE) and ...